answer text |
<p>The information is not available in the format requested. Such information as is
available is shown in the table below and is from reference costs, which are the average
unit cost to National Health Service trusts and foundation trusts of providing defined
services in a given financial year. Reference costs are published annually, with most
recently available data being for 2014-15.</p><p> </p><p>Reference costs for acute
care are collected by healthcare resource group (HRG), which are standard groupings
of clinically similar treatments that consume similar levels of healthcare resource.
HRGs are organised by chapters and sub-chapters, representing different body systems,
and HRG sub-chapters GC and PG describe hepatobiliary and pancreatic system disorders
for adults and children respectively. The average costs in the following table will
therefore include the costs to NHS hospitals of treating decompensated cirrhosis of
the liver and hepatocellular carcinoma, as well as the costs of other related disorders.</p><p>
</p><p>These costs do not include high cost drugs, or treatment in outpatient or other
settings outside of hospital. They reflect the costs of a single episode of care under
one consultant for a patient admitted to hospital for either elective or non-elective
treatment. Patients admitted to hospital may have multiple episodes of care and each
one of these episodes will be recorded separately.</p><p> </p><p>Total cost to NHS
hospitals of treating hepatobiliary and pancreatic system disorders, 2014-15</p><table><tbody><tr><td><p>
</p></td><td><p>Average cost per Finished Consultant Episode (£)</p></td></tr><tr><td><p>Malignant,
Hepatobiliary or Pancreatic Disorders<sup>1</sup></p></td><td><p>1,984</p></td></tr><tr><td><p>Non-Malignant,
Hepatobiliary or Pancreatic Disorders<sup>2</sup></p></td><td><p>1,751</p></td></tr><tr><td><p>Paediatric,
Hepatobiliary or Pancreatic Disorders<sup>3</sup></p></td><td><p>2,344</p></td></tr></tbody></table><p><em>Source:
</em>Reference costs, Department of Health</p><p> </p><p><em>Notes:</em></p><p>1.
The following HRGs are included in the table:</p><p>GC12C Malignant, Hepatobiliary
or Pancreatic Disorders, with Multiple Interventions</p><p>GC12D Malignant, Hepatobiliary
or Pancreatic Disorders, with Single Intervention, with CC Score 5+</p><p>GC12E Malignant,
Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 2-4</p><p>GC12F
Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC
Score 0-1</p><p>GC12G Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions,
with CC Score 6+</p><p>GC12H Malignant, Hepatobiliary or Pancreatic Disorders, without
Interventions, with CC Score 3-5</p><p>GC12J Malignant, Hepatobiliary or Pancreatic
Disorders, without Interventions, with CC Score 1-2</p><p>GC12K Malignant, Hepatobiliary
or Pancreatic Disorders, without Interventions, with CC Score 0</p><p>2. GC17A Non-Malignant,
Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score
9+</p><p>GC17B Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple
Interventions, with CC Score 4-8</p><p>GC17C Non-Malignant, Hepatobiliary or Pancreatic
Disorders, with Multiple Interventions, with CC Score 0-3</p><p>GC17D Non-Malignant,
Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 9+</p><p>GC17E
Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with
CC Score 4-8</p><p>GC17F Non-Malignant, Hepatobiliary or Pancreatic Disorders, with
Single Intervention, with CC Score 0-3</p><p>GC17G Non-Malignant, Hepatobiliary or
Pancreatic Disorders, without Interventions, with CC Score 8+</p><p>GC17H Non-Malignant,
Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 5-7</p><p>GC17J
Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with
CC Score 2-4</p><p>GC17K Non-Malignant, Hepatobiliary or Pancreatic Disorders, without
Interventions, with CC Score 0-1</p><p>3. PG71A Paediatric, Hepatobiliary or Pancreatic
Disorders, with CC Score 2+</p><p>PG71B Paediatric, Hepatobiliary or Pancreatic Disorders,
with CC Score 1</p><p>PG71C Paediatric, Hepatobiliary or Pancreatic Disorders, with
CC Score 0</p><p>4. These HRGs are common groupings of the ICD-10 codes used to count
the number of finished admission episodes with a primary or secondary diagnosis of
hepatocellular carcinoma or decompensated cirrhosis. They also include other ICD-10
codes</p><p>5. For each HRG or other currency in the reference cost collection, NHS
hospital trusts submit a unit cost and amount of activity undertaken.</p>
|
|